Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01104922 · ClinicalTrials.gov registry record · Phase 2
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study, sponsored by David A. Clump, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01104922 is a Phase 2 study that has completed, run by David A. Clump, MD, PhD. The registered enrollment target is 48 participants.
The verdict
NCT01104922, a Phase 2 study, has completed, sponsored by David A. Clump, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This trial examines survival and toxicity in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN) treated with radiosurgery and cetuximab and to evaluate the acute and late toxicities associated with the above therapy.
Interventions
- DRUG Cetuximab
- DEVICE Stereotactic radiosurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-12-26 |
| Est. Completion | 2018-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01104922
The ClinicalTrials.gov registry entry for NCT01104922 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David A. Clump, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT01104922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01104922 about?
NCT01104922 is a clinical study titled "Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck". This trial examines survival and toxicity in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN) treated with radiosurgery and cetuximab and to evaluate the acute and late toxicities associated with the above therapy.
What is the current status of trial NCT01104922?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2007-12-26. Estimated completion is 2018-07-26.
What interventions are being tested in trial NCT01104922?
The interventions under investigation include: Cetuximab (DRUG), Stereotactic radiosurgery (DEVICE).
Who is sponsoring clinical trial NCT01104922?
This trial is sponsored by David A. Clump, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.